ARIX.L

Arix Bioscience Plc
Arix Bioscience Plc - Director/PDMR Shareholding
4th May 2023, 16:02
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4854Y
Arix Bioscience Plc
04 May 2023
 

Arix Bioscience plc
("Company")

PDMR notifications & Director Shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The Company has been notified that Robert Lyne, Chief executive Officer, has sold a total of 107,657 Ordinary shares of 0.001 pence each in the Company ("Shares") on 04 May 2023 at an average price of 105 pence per share and bought on 04 May 2023, into his ISAs and SIPP, a total of 107,657 Shares at an average price of 107 pence per share.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further detail on the respective transactions.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne  

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share Disposal

 c)

Price(s) and volume(s)


Price(s)£

Volume(s)




1.)      £1.052

 

2.)       £1.053

 

3.)       £1.0526

 

4.)       £1.0425

 

22,238

20,000


8,419

57,000


d)

 

Aggregated information


- Aggregated volume

 107,657

- Price (£)

 £112,669.14

e)

 

Date of the transaction

 

4 May 2023

f)

 

Place of the transaction

 

London Stock Exchange

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne  

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share Purchase 

 c)

Price(s) and volume(s)


Price(s)(£)

Volume(s)




£1.069

£1.069

£1.068

 

57,014

8,419

42,224


d)

 

Aggregated information


- Aggregated volume

  107,657

- Price (£)

  £115,094.42

e)

 

Date of the transaction

 

4 May 2023

f)

 

Place of the transaction

 

London Stock Exchange

 

Ends.

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
 +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQZLFBXELBBBB ]]>
TwitterFacebookLinkedIn